1. Practice patterns and recurrence after partial cystectomy for bladder cancer
- Author
-
Armen Aprikian, Moamen Amin, Nader Fahmy, Simon Tanguay, Wassim Kassouf, Suganthiny Jeyaganth, Mohammed Al-Otaibi, and Salaheddin M. Mahmud
- Subjects
Male ,medicine.medical_specialty ,Databases, Factual ,Urology ,medicine.medical_treatment ,Urinary system ,Population ,Kaplan-Meier Estimate ,Cystectomy ,Prevalence ,medicine ,Humans ,education ,Aged ,Salvage Therapy ,education.field_of_study ,Urinary bladder ,Bladder cancer ,business.industry ,Quebec ,Cancer ,Professional Practice ,Middle Aged ,medicine.disease ,Surgery ,medicine.anatomical_structure ,Urinary Bladder Neoplasms ,Concomitant ,Lymph Node Excision ,Female ,Lymphadenectomy ,Neoplasm Recurrence, Local ,business - Abstract
Partial cystectomy (PC) remains a viable alternative to radical cystectomy (RC) for management of invasive bladder cancer in approximately 5% of patients. We used a population-based database to examine practice patterns and recurrence after partial cystectomy. We obtained billing records of all partial and radical cystectomies performed for bladder cancer in Quebec from 1983 until 2005. Analysis included age, gender, year of surgery, surgeon’s age, hospital type, preoperative and postoperative visits with accompanying diagnoses and dates of recurrences salvage RC, and death. A total of 714 (30.4%) patients with invasive bladder cancer underwent PC. Majority of PC (65%) were performed in non-academic institutions. Pelvic lymphadenectomy was performed in only 163 patients (23%) and concomitant ureteral reimplantation was performed in 89 patients (13%). Of 714 patients, 52 (23.7%) required a salvage RC. Median time from PC to salvage RC was 17.6 months (range 1–240 months), respectively. Patients who underwent PC had similar 5-year overall survival compared with patients who underwent upfront RC (49.8% vs. 51%, p = 0.21). Rate of PC for invasive bladder cancer is significantly higher than expected. Pelvic lymphadenectomy is underutilized in bladder cancer patients treated with PC. Whether prevalent use of PC is due to less stringent selection criteria remains unknown. Since late recurrence is not uncommon, lifelong follow-up is recommended.
- Published
- 2009
- Full Text
- View/download PDF